Member Info for Dosanddonts

Haleon said within the next 12month in Feb24! So an early launch is feasible. Be interesting when the buying starts as the launch date is unknown and could come at anytime!

Until this reaches US market or FUM give us more financial data then the SP will be erratic. No reason for the sudden uplift, no real volume of shares changing hands! This is being played & until Haleon announce release date then it will continue! Question is who is willing to sell & take the chance to buy back in lower NOT me! But wish I had over the years, End game is in sight!

My thoughts were that Haleon may take the distribution for China! & maybe that’s why no deal has been struck! Especially with a product like Eroxon that could increase their exposure.

I personally can’t see the point in the company anymore as it only exists for Eroxon! Haleon are doing everything their end from manufacture to distribution, coopers only distribution with 3rd party manufacture. Once the outstanding deals are completed then the BoD are redundant in my eyes, not much to develop & expand the range with really.

The new website now only mentions Eroxon & sexual health, no mention of the technology Dermasys! So they have clearly thrown all their eggs into one basket! Clearly have been advised to do this & hopefully for a sale of the company at some point in the near future. Although I’m frustrated with the SP & the BoD, I do think we will see decent returns soon as do LO/ADAMS & the other major investors who are holding strong!

The BoD have been milking the cow for the last 20 years, and will continue to do so, as well as taking a bloody good salary to go with that! They have given up on all other products yet say they are good at R&D, well if that was the case why didn’t they get other products to market successful! And let’s be honest they stumbled onto Eroxon by accident in the end! Let’s face it JB is an insurance broker by trade and AH sells alcoholic drinks at wedding venues from a mobile pub? Not really the credentials we want running FUM! Surely time for LB to take a majority stake & dump these two clowns not reward them. RNS states when milestones are met what are they??

Never ever expected SP to be at this point, seems mad that anyone can get onboard and almost guarantee a 300% increase within 24month or maybe earlier? So much for the get in early to reap the rewards and the so called long term investment! Investors who have jumped in & out have made a fortune and the late arrivals to the party will see gains with little time invested. I see RNS’s being released all the time to bump up the SP, only for a fund raise soon after! FUM have done it in the past as well! Yet they can’t be bothered to release RNS’s now and can’t even give a decent financial forecast JOKE! Please someone buy these morons out discard the current BOD.

Think they need to get the male version over the line first & generate some returns for shareholders. They had several potential products like TPR100 pain relief, spent millions and told us all the commercial potential was massive, they were actually working on the final stages! Now just dropped it & thats fine but Eroxon still needs to prove itself in the biggest market of all, as does the Brand Eroxon! all those negative reviews need addressing as not being followed up with positives even now a year on! Something else they have no control over but need to do something about before extending the range.

It seems FUM have removed everything from their website but Eroxon / Med3000, no mention of dermasys technology either. Is this a plan for selling the company and then focusing on these other products as a separate entity?? A sexual health company with one product? Clearly they have been told that this is the way forward to attract investors & make the company more attractive. Seems strange to me as gone from a company with multiple potential products to one? As an investor this is less attractive to me! I suspect this is the case that the two names futura medical & Eroxon are intertwined and would need to be sold together, so the focusing on one product & sexual health is a focus on selling the business if the opportunity arises. IMO

Against my better judgment topped up, no bad news so why not all positive really so it’s hopefully a no brainer! If you listen to the presentation the CFO keeps on stating we can’t and won’t release the US launch date, as if they know when it will be? just reiterating the 12month from Feb that Haleon announced! Basically 10 month now, Jesus I’ve been here years and years forgot how many now, but 10 months is a drop in the ocean! I know I said I’d be out if no new announcements but Hey just can’t give up on the guaranteed payday coming very soon!

If this pulls back any further maybe us PI’s should club together and takeover? Barder should be worried with a SP this low as they are vulnerable to a hostile takeover!

FUM Valued £110m, they are expecting £5mill when sales start in US, then potential £45mill of sales milestones that they say are very easily achievable and how much are FUM royalties? A buyout seems inevitable! If Haleon bought them out they would save £50mill and take full royalties? At an initial cost of £300mill seems like a steal to me, and based on FUM staff levels could incorporate into current business and get shot of the dead wood guess who? Not needed!

A lot of these articles appear to be written by AI as little research done!

Barder states in presentation that they are not taking sales from products like viagra or Cialis, they are creating a new market with new customers. so if that’s the case why would these companies aggressively target Eroxon during launches to hamper sales?? They may have, when product was first released but based on this info would be a waste of money wouldn’t it? He just likes the words commercially sensitive, has to get those words in as many times as he can!😂

Disappointed but expected let’s face it, and Barder it’s not that you look miserable (from proactive video his words). It’s the cheesy smirk & the fact that when you speak we never get an answer just like a politician that we dislike DYOR! His likeness to a politician is unreal, when the company is bought out & he’s moved on, he has a calling!

Why have they not give an indication of revenue /sales forecast for 2024? We are now pretty much in all key EU markets as well as Saudi ( zero feedback on that one considering it is one of the most lucrative markets) and yet no forecast pathetic IMO! Get rid of that CFO who’s it is to forecast these things useless!

I expect a detailed plan of rollout execution across all approved markets including US, with an update on sales across all territories. An explanation as why they haven’t hit the 10 additional rollouts promised and a strategic plan for restarting other product R&D. I hope it’s not wishy washy BS we have already heard.

RNS states investor presentation as well as financial results! This is not the normal year on year results only! and can only assume that the BOD recognises that private investors are entitled to more information with a mention of answering investors submitted questions! I’m in hope of a positive outcome on the 10th otherwise I’m out!

I don’t think the BOD will have left themselves open to Haleon delays, they terminated the china deal because they hadn’t met deadlines, so same will apply with Haleon! Milestones must be being met, and as pointed out they have been caught out before so doubt they will let it happen again!

FUM have already declared they are achieving 20% market share, if this has been maintained since last update then surely this is a better indication of repeat sales? I would like % of ED market taken in other territories if we are looking at 20% across the board then happy days! you do the maths.